Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Clinical Chemistry Instruments and Reagents Under Scrutiny at the 2015 AACC Annual Meeting

By LabMedica International staff writers
Posted on 27 Jul 2015
Clinical chemistry, both instrumentation and reagents, was the focus of presentations at booth 1018 at the 2015 AACC Annual Meeting & Clinical Lab Expo (Atlanta, GA, USA).

EKF Diagnostics (Cardiff, United Kingdom), a global in vitro diagnostics company, took advantage of the AACC Annual Meeting to launch the Altair 240 clinical chemistry analyzer.

This new bench-top platform represents EKF Diagnostics’ first fully integrated chemistry system designed for the global market. More...
EKF believes that the new Altair 240 clinical chemistry analyzer fulfills an international market need for a fully automated bench-top platform supported by the reliable Stanbio Chemistry (Boerne, TX, USA) reagent menu.

“We listened to the needs of our customers and designed the Altair 240 to be easy to learn, operate, and maintain,” said Albert Blanco, business unit director at EKF Diagnostics. “Because it runs on Windows 7, operators can easily navigate its intuitive, touch screen menu. Features such as the capability to use bar coded, primary sample tubes, auto-rerun, auto-dilution and STAT interruption—all function to maximize the system’s overall efficiency.”

EKF will also use the AACC Annual Meeting venue to discuss the latest additions to its Stanbio clinical chemistry range. This range includes a large selection of clinical chemistry assays, controls, and calibrators, which are fully compatible with most major brand open channel chemistry analyzers.

A notable addition to the reagent menu is the Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor test; a new diabetes biomarker test that provides a two to three week indicator of average blood glucose. The GSP LiquiColor test is based on a double enzymatic degradation method that utilizes the specificity of fructosyl-amino oxidase to eliminate inaccuracies caused by non-glycated protein reducing substances, which significantly interfere with the NBT fructosamine method. The test is available as a liquid-stable kit with calibrator. It is suitable for use on a variety of clinical chemistry analyzers, with on-board stability of up to four weeks.

Other instruments to be highlighted at the AACC Annual Meeting include the DiaSpect and HemoPoint H2. DiaSpect is a hand held device touted as being the world’s fastest hemoglobin measurement system. The instrument is described as offering laboratory quality performance for anemia screening in all climatic conditions in less than two seconds. The HemoPoint H2 stores over 4000 patient results and is designed for use in blood banks, clinics, and hospitals. This instrument provides immediate and simultaneous high quality results for both hemoglobin and hematocrit.

Related Links:

2015 AACC Annual Meeting & Clinical Lab Expo
EKF Diagnostics
Stanbio Chemistry



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.